Symphogen

Symphogen is a Copenhagen-based biotechnology company founded in 2000 that develops antibody medicines using mixtures of carefully selected recombinant monoclonal antibodies. Its approach is intended to combine some of the breadth associated with naturally occurring polyclonal immune responses with the defined composition, reproducibility, and manufacturing control of monoclonal antibodies. Rather than relying on antibodies harvested from biological sources, Symphogen engineers individual antibody-producing cell lines and combines them into a controlled therapeutic mixture. The company’s research has centered on three broad areas: immunoglobulin replacement, cancer, and infectious diseases. Its technology platform is designed for diseases in which a single antibody specificity may be insufficient. A mixture can bind several epitopes on a target, address more than one biological mechanism, and potentially reduce the impact of antigenic variation such as viral escape mutations. Symphogen has described additional possible advantages, including the formation of larger immune complexes and stronger activation of downstream immune functions such as complement activity, phagocytosis, and antibody-dependent cellular cytotoxicity. Symphogen’s discovery platform, Symplex, isolates antibody genes from immune cells and preserves naturally paired heavy- and light-chain sequences. The process includes isolating relevant immune cells, sorting individual B cells, amplifying antibody genes, cloning the paired sequences, and screening the resulting antibodies for therapeutic properties. The company’s manufacturing platform, Sympress, is intended to produce consistent antibody mixtures at industrial scale. It uses mammalian cell systems, including Chinese hamster ovary cells, with selected cell lines combined to generate the desired mixture. Sympress II was developed to improve expression yields through random gene integration. By 2009, Symphogen had reported ten drug programs in development. Rozrolimupab, also known as Sym001, was its lead program. This recombinant antibody mixture was designed for hematological indications, including idiopathic thrombocytopenic purpura and hemolytic disease of the newborn, and received orphan-drug designation in the United States. Sym004, a two-antibody treatment directed at the epidermal growth factor receptor, was another leading program and entered clinical development for colorectal cancer and squamous cell carcinoma of the head and neck. The two antibodies were selected to bind different EGFR epitopes and work together to promote receptor internalization and degradation. The company formed development and commercialization relationships with organizations including Genentech, Meiji Seika Kaisha, Biovitrum, and the U.S. National Institute of Allergy and Infectious Diseases. These collaborations covered antibody discovery, development, licensing, commercialization, and preclinical work in infectious diseases and oncology. A grant-supported program, Sym002, was aimed at a recombinant antibody mixture against smallpox and was intended to support preclinical development toward an Investigational New Drug submission. In 2020, Laboratoires Servier acquired Symphogen. The acquisition placed Symphogen’s antibody discovery and development capabilities within Servier’s broader pharmaceutical group. Publicly available reference material describes Symphogen primarily through its platform technologies and pipeline rather than through marketed products. Its strategic significance lies in developing reproducible, multi-antibody biologics for complex diseases where simultaneous engagement of multiple epitopes or targets may offer an advantage over single-antibody treatment.

Symphogen was established in Denmark in 2000 as a biotechnology company specializing in recombinant antibody mixtures. Its central scientific proposition was that a therapeutic could contain multiple defined monoclonal antibodies while avoiding the compositional uncertainty associated with conventional polyclonal antibodies. Each antibody in a Symphogen mixture is derived from a selected clone and directed at a particular epitope. The resulting product is therefore manufactured as a controlled combination of monoclonal antibodies rather than as an antibody preparation harvested from serum or another variable biological source. The company built its work around two proprietary platforms. Symplex was designed for antibody discovery. It involved isolating immune cells from animal or human sources, separating and sorting individual B lymphocytes, recovering antibody genes, preserving naturally paired heavy- and light-chain sequences, and expressing and screening the resulting antibodies. This process was intended to retain useful immune-system diversity while allowing the company to select individual antibodies according to binding and functional properties. Sympress was the corresponding production platform. It used mammalian expression systems, including Chinese hamster ovary cells, to produce the selected antibodies. Individual cell lines were screened for expression and quality, preserved in cell banks, and combined to produce a consistent mixture. Sympress I supported development of Sym001, while Sympress II was described as a later manufacturing approach intended to improve yields through random gene integration. Together, the platforms were meant to support a complete path from antibody discovery to reproducible large-scale manufacture. Symphogen’s therapeutic research covered immunoglobulin replacement, oncology, and infectious diseases. The company argued that recombinant antibody mixtures could address several epitopes simultaneously, reduce sensitivity to antigenic diversification, create larger immune complexes, and stimulate immune effector mechanisms. These properties were particularly relevant to infectious diseases with rapidly changing antigens and cancers involving complex signaling networks. By 2009, the company reported a pipeline of ten development programs. Sym001, later known as rozrolimupab, became the lead program. It consisted of twenty-five monoclonal antibodies and was investigated for hematological conditions including idiopathic thrombocytopenic purpura and hemolytic disease of the newborn. The program received orphan-drug designation from the U.S. Food and Drug Administration and was developed with Biovitrum under a co-development and commercialization agreement. Sym004 was another prominent program. It combined two chimeric antibodies, identified as 992 and 1024, that bound different sites on the epidermal growth factor receptor. Their combined activity promoted receptor cross-linking, internalization, and degradation. Preclinical work indicated greater activity from the combination than from either antibody alone in selected cancer models. The program advanced into clinical studies for colorectal cancer and squamous cell carcinoma of the head and neck. Phase I studies were reported as completed in 2011, followed by a Phase II study at Antwerp University Hospital. Reported adverse effects in preclinical work included rash and diarrhea, consistent with EGFR expression in skin and the gastrointestinal tract. The company also pursued infectious-disease programs and technology partnerships. A collaboration with Genentech covered use of Symplex to discover antibodies against undisclosed infectious-disease targets. An agreement with Meiji Seika Kaisha addressed research, development, and commercialization of Sym006. With the National Institute of Allergy and Infectious Diseases, Symphogen worked on Sym002, a recombinant antibody mixture against smallpox supported by a developmental grant intended to advance preclinical work toward an Investigational New Drug application. In 2020, Laboratoires Servier acquired Symphogen. This transaction marked the integration of Symphogen’s antibody platforms and development capabilities into a larger pharmaceutical organization. The available reference material does not establish whether Symphogen continued to operate as a standalone commercial brand, nor does it identify any marketed product. Its documented legacy is therefore primarily technological and pipeline-based: the development of reproducible recombinant multi-antibody medicines and the platforms intended to discover and manufacture them.

• 2020

  Acquisition by Laboratoires Servier

  [1]Symphogenen.wikipedia.org

  Laboratoires Servier acquires Symphogen and incorporates its antibody platforms and development capabilities into the Servier group.

• 2011

  Sym004 advances into Phase II studies

  [1]Symphogenen.wikipedia.org

  Following Phase I work, Sym004 enters Phase II clinical development for colorectal cancer and squamous cell carcinoma of the head and neck.

• 2009

  Pipeline reaches ten reported development programs

  [1]Symphogenen.wikipedia.org

  The company reports that ten drug candidates are in development, with Sym001 identified as the lead program.

• 2000

  Symphogen is founded

  [1]Symphogenen.wikipedia.org

  Symphogen is established as a biotechnology company in Denmark, with a focus on recombinant mixtures of monoclonal antibodies.

A biotechnology specialist in controlled recombinant mixtures of monoclonal antibodies, positioned between conventional single monoclonal-antibody medicines and source-derived polyclonal immunoglobulin products.

• Recombinant multi-antibody therapeutic

  Sym001 (rozrolimupab)

  Sym001, also known as rozrolimupab, is a recombinant antibody mixture comprising twenty-five monoclonal antibodies. It was developed for hematological applications, including idiopathic thrombocytopenic purpura and hemolytic disease of the newborn. The program was associated with Biovitrum through a co-development and commercialization agreement and received orphan-drug designation from the U.S. Food and Drug Administration. It was one of Symphogen’s lead clinical programs.

• Oncology antibody combination

  Sym004

  Sym004 is a combination of two chimeric monoclonal antibodies, identified as 992 and 1024, that bind different epitopes on the epidermal growth factor receptor. Their combined action was designed to promote EGFR cross-linking, internalization, and degradation, thereby suppressing receptor signaling and tumor-cell growth. The program entered clinical studies in colorectal cancer and squamous cell carcinoma of the head and neck. Phase I studies were reported as completed in 2011, followed by Phase II development.

• Infectious-disease antibody program

  Sym002

  Sym002 was a recombinant polyclonal or multi-antibody program directed against smallpox. Its preclinical development was supported by a grant from the U.S. National Institute of Allergy and Infectious Diseases. The stated purpose of the support was to help Symphogen complete preclinical work and prepare for submission of an Investigational New Drug application for additional safety studies.

• Antibody-discovery platform

  Symplex

  Symplex is Symphogen’s antibody-discovery technology. It isolates antibody genes from individual immune cells, maintains naturally paired heavy- and light-chain sequences, clones the genes, and expresses and screens the resulting antibodies. The platform was intended to identify fully human or otherwise therapeutically relevant antibodies with selected binding and functional characteristics for subsequent development.

• Antibody-manufacturing platform

  Sympress

  Sympress is Symphogen's manufacturing technology for producing consistent mixtures of recombinant antibodies at scale. It uses selected mammalian cell lines, including Chinese hamster ovary cells, to express the individual antibodies and combine them into a defined product. Sympress I was used in connection with Sym001, while Sympress II was developed to improve expression yields through random gene integration.

• 2020

  Join the Laboratoires Servier groupM&A

  Background

  Symphogen had developed antibody-discovery and antibody-manufacturing technologies together with a clinical and preclinical pipeline focused on oncology, infectious diseases, and immunology.

  Action taken

  Laboratoires Servier acquired Symphogen and brought the company’s capabilities into its pharmaceutical group.

  Aftermath

  The acquisition integrated Symphogen with Servier, although the available reference material does not specify the subsequent standalone status of the Symphogen name or individual pipeline programs.

  Source

• 2011

  Advance Sym004 into Phase II clinical testingProduct launch

  Background

  Preclinical studies indicated that the two antibodies in Sym004 could cooperate by binding separate EGFR epitopes and promoting receptor internalization and degradation.

  Action taken

  Symphogen began Phase II evaluation of Sym004 in patients with colorectal cancer and squamous cell carcinoma of the head and neck.

  Aftermath

  The program continued clinical evaluation of safety, efficacy, and pharmacokinetics; no later outcome is established by the supplied material.

  Source

• 2020-06-04

  Servier completes acquisition of Symphogen[2]施维雅完成对Symphogen的收购prnasia.com

  Reported: 2020-06-04

  Servier announced that it had completed its acquisition of Symphogen A/S. Symphogen will operate as an antibody center of excellence within Servier and retain operational autonomy, its employees and its headquarters in Ballerup, Denmark.

1. 1Symphogenen.wikipedia.org
2. 2施维雅完成对Symphogen的收购prnasia.com